Cochrane Infectious Diseases Group, UK

Main interests

The CIDG’s main areas of work are on determination of the effects of interventions on the prevention or treatment of infectious diseases of relevance to the United Nations Sustainable Development Goals, particularly malaria, tuberculosis, HIV/AIDS, and neglected tropical diseases in low- and middle-income countries.

The aims of the CIDG are to impact on policy and research in tropical diseases through the production of high quality and relevant systematic reviews and to lead developments in review quality improvement and effective dissemination of findings.


  • has over 700 active authors from around the world currently preparing or updating Cochrane systematic reviews.
  • includes 20 international Editors, Co-ordinating Editor, Managing Editor, Statistician, Information Specialists, Editorial Assistants, and Specialist Advisors.
  • provides training and support for author teams in preparing and updating reviews, and methodological help in all aspects of research synthesis, including preparing 'Summary of findings' tables.

Current publications

Public health deworming programmes for soil-transmitted helminths in children living in endemic areas (September 2019)

Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults (June 2019)

Vaccines for preventing diarrhoea: vaccines in use (March 2019)

Cochrane Infectious Diseases works with WHO on latest malaria vector control guidelines (February 2019)

Being HIV positive and staying on antiretroviral therapy in Africa (January 2019)

Pyronaridine‐artesunate for treating uncomplicated Plasmodium falciparum malaria (January 2019)

Albendazole alone or in combination with microfilaricidal drugs for lymphatic filariasis (January 2019)

Buddies project-dialogue with policy makers (December 2018)

Updating guidance on cryptococcal disease (December 2018)

Supplementary feeding in food insecure populations-an overview (November 2018)

Plagiarism in African journals (November 2018)

Norovirus infection (October 2018)

Revision of ARRIVE Guidelines (June 2018)